Leading biotechnology company Cellular Engineering Technologies (CET), based in Coralville, Iowa, provides optimized reagents and human cell lines that address the technical and clinical challenges of developing next-generation cell therapies and regenerative medicines. Focus areas include stem cell research, drug discovery, and cell manufacturing for therapeutic applications. Founded in 2000, CET is committed to improving workflow efficiencies, enhancing safety profiles, and lowering the cost of developing cell-based therapies.
Worldwide, CET is perhaps most widely recognized for their patented virus-free and oncogene-free induced pluripotent stem cell (iPSC) technology, which provides better predictability for drug discovery and enhanced safety in cell therapy applications. Their portfolio of human somatic stem cells and iPSCs produce the safest and most scalable starting cell lines for research and manufacturing needs. Using CET's iPSC reprogramming kits, researchers can generate iPSC colonies safely and efficiently in-house, while their iPSC Growth Media delivers best-in-class cell expansion and viability for research budgets.
Quality products, expert technical service, and innovative first-principles problem solving are at the core of CET's mission to accelerate research in regenerative medicine and cell therapy.